Clinical Trial Update: Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating cabozantinib in patients with advanced pancreatic neuroendocrine tumors and carcinoid tumors; results have been posted as of 2024-10-16…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Cabometyx (cabozantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-16